To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Clinical trial NCT05468489 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05468489
- Sponsor
- Shanghai Henlius Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-18
- Primary completion
- 2026-02-28
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.